Introduktion
Denne side giver en omfattende analyse af den kendte insiderhandelshistorie for David V Goeddel. Insidere er embedsmænd, direktører eller betydelige investorer i en virksomhed. Det er ulovligt for insidere at foretage handler i deres virksomheder baseret på specifik, ikke-offentlig information. Dette betyder ikke, at det er ulovligt for dem at handle i deres egne virksomheder. De skal dog rapportere alle handler til SEC via en formular 4. På trods af disse begrænsninger tyder akademisk forskning på, at insidere - generelt - har en tendens til at klare sig bedre end markedet i deres egne virksomheder.
Gennemsnitlig handelsrentabilitet
Den gennemsnitlige handelsrentabilitet er det gennemsnitlige afkast af alle køb på det åbne marked foretaget af insideren i de sidste tre år. For at beregne dette undersøger vi ethvert åbent marked, uplanlagte køb foretaget af insideren, eksklusive alle handler, der var markeret som en del af en 10b5-1-handelsplan. Vi beregner derefter den gennemsnitlige præstation for disse handler over 3, 6 og 12 måneder, idet vi tager et gennemsnit af hver af disse varigheder for at generere en endelig præstationsmåling for hver handel. Endelig tager vi et gennemsnit af alle præstationsmålingerne for at beregne en præstationsmåling for insideren. Denne liste inkluderer kun insidere, der har foretaget mindst tre handler i de sidste to år.
Hvis denne insiderhandelsrentabilitet er "N/A", så har insideren enten ikke foretaget nogen køb på det åbne marked i de sidste tre år, eller de handler, de har foretaget, er for nye til at beregne en pålidelig præstationsmåling.
Opdateringsfrekvens: Dagligt
Virksomheder med rapporterede insider-stillinger
SEC-registreringen viser, at David V Goeddel har rapporteret besiddelser eller handler i følgende virksomheder:
Sikkerhed | Titel | Senest indberettede beholdninger |
---|---|---|
US:TNYA / Tenaya Therapeutics, Inc. | Director, 10% Owner | 49.313.559 |
US:RAPT / RAPT Therapeutics, Inc. | 10% Owner | 0 |
US:NGM / NGM Biopharmaceuticals, Inc. | Director, 10% Owner | 1.000 |
US:ORIC / ORIC Pharmaceuticals, Inc. | 10% Owner | 74 |
US:EFTR / eFFECTOR Therapeutics, Inc. | 10% Owner | 4.309.329 |
US:NRIX / Nurix Therapeutics, Inc. | 10% Owner | 48.406 |
10% Owner | 99.155 | |
US:RVMD / Revolution Medicines, Inc. | 10% Owner | 2.429.180 |
US:IMDZ / Immune Design Corp. | 10% Owner | 0 |
US:GRTS / Gritstone bio, Inc. | 0 | |
US:RCUS / Arcus Biosciences, Inc. | 10% Owner | 0 |
Sådan fortolkes diagrammerne
Følgende diagrammer viser aktieudviklingen for værdipapirer efter hver åben-marked, ikke-planlagt handel foretaget af David V Goeddel. Ikke-planlagt handel er handler, der ikke blev foretaget som en del af en 10b5-1-handelsplan. Aktieudviklingen er kortlagt som den kumulative procentvise ændring i aktiekursen. For eksempel, hvis en insiderhandel blev foretaget den 1. januar 2019, vil diagrammet vise den daglige procentvise ændring af værdipapiret til i dag. Hvis aktiekursen skulle gå fra $10 til $15 i løbet af denne tid, ville den kumulative procentvise ændring i aktiekursen være 50%. En prisændring fra 10 USD til 20 USD ville være 100 %, og en ændring i prisen på 10 USD til 5 USD ville være -50 %.
I sidste ende forsøger vi at bestemme, hvor tæt insiderens handler korrelerer med merafkast (positive eller negative) i aktiekursen for at se, om insideren timing deres handler til at drage fordel af insiderinformation. Overvej situationen, hvor en insider gjorde dette. I denne situation ville vi forvente enten (a) positive afkast efter køb eller (b) negative afkast efter salg. I tilfælde af (a) vil KØB-diagrammet vise en række opadskrånende kurver, der indikerer positive afkast efter hver købstransaktion. I tilfælde af (b) vil SALE-diagrammet vise en række nedadgående kurver, der indikerer negative afkast efter hver salgstransaktion.
Dette alene er dog ikke nok til at drage konklusioner. Hvis for eksempel aktiekursen i selskabet var i en ikke-cyklisk stigning over mange år, så ville vi forvente, at alle efterkøbsgrundene var opadgående. Ligeledes ville ikke-cykliske fald over mange år resultere i nedadgående post-trade plots. Ingen af disse diagrammer tyder på insiderhandel.
Den stærkeste indikator ville være en situation, hvor aktiekursen var ekstremt cyklisk, og der var både positive signaler i KØB-diagrammet og negative plots på SALG-diagrammet. Denne situation ville i høj grad tyde på en insider, der havde timing af handler til deres økonomiske fordel.
Insiderkøb EFTRW / eFFECTOR Therapeutics, Inc. - Equity Warrant – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i EFTRW / eFFECTOR Therapeutics, Inc. - Equity Warrant. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg EFTRW / eFFECTOR Therapeutics, Inc. - Equity Warrant – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i EFTRW / eFFECTOR Therapeutics, Inc. - Equity Warrant. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb NRIX / Nurix Therapeutics, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i EFTRW / eFFECTOR Therapeutics, Inc. - Equity Warrant. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg NRIX / Nurix Therapeutics, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i EFTRW / eFFECTOR Therapeutics, Inc. - Equity Warrant. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb ORIC / ORIC Pharmaceuticals, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i EFTRW / eFFECTOR Therapeutics, Inc. - Equity Warrant. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg ORIC / ORIC Pharmaceuticals, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i EFTRW / eFFECTOR Therapeutics, Inc. - Equity Warrant. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb RAPT / RAPT Therapeutics, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i EFTRW / eFFECTOR Therapeutics, Inc. - Equity Warrant. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg RAPT / RAPT Therapeutics, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i EFTRW / eFFECTOR Therapeutics, Inc. - Equity Warrant. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb RCUS / Arcus Biosciences, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i EFTRW / eFFECTOR Therapeutics, Inc. - Equity Warrant. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg RCUS / Arcus Biosciences, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i EFTRW / eFFECTOR Therapeutics, Inc. - Equity Warrant. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb RVMD / Revolution Medicines, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i EFTRW / eFFECTOR Therapeutics, Inc. - Equity Warrant. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg RVMD / Revolution Medicines, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i EFTRW / eFFECTOR Therapeutics, Inc. - Equity Warrant. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb TNYA / Tenaya Therapeutics, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i EFTRW / eFFECTOR Therapeutics, Inc. - Equity Warrant. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg TNYA / Tenaya Therapeutics, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i EFTRW / eFFECTOR Therapeutics, Inc. - Equity Warrant. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderhandelshistorie
Denne tabel viser den komplette liste over insiderhandler foretaget af David V Goeddel som oplyst til Securities Exchange Commission (SEC).
Fil dato | Transdato | Form | Ticker | Sikkerhed | Kode | Aktier | Resterende aktier | Procent Lave om |
Del Pris |
Tran Værdi |
Tilbage Værdi |
|
---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-03-07 |
|
4 | TNYA |
Tenaya Therapeutics, Inc.
Common Stock |
P - Purchase | 35.714.284 | 49.313.559 | 262,62 | 0,70 | 24.999.999 | 34.519.491 | |
2024-12-23 |
|
4 | RAPT |
RAPT Therapeutics, Inc.
Common Stock |
J - Other | -1.599.417 | 0 | -100,00 | ||||
2024-12-23 |
|
4 | RAPT |
RAPT Therapeutics, Inc.
Common Stock |
J - Other | -1.352.008 | 50.000 | -96,43 | ||||
2024-04-08 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
J - Other | 1.000 | 1.000 | |||||
2024-04-08 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
D - Sale to Issuer | -100.000 | 0 | -100,00 | ||||
2024-04-08 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
D - Sale to Issuer | -100.000 | 0 | -100,00 | ||||
2024-04-08 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
D - Sale to Issuer | -1.298.908 | 0 | -100,00 | ||||
2024-04-08 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
D - Sale to Issuer | -1.298.908 | 0 | -100,00 | ||||
2024-04-08 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
D - Sale to Issuer | -2.265.758 | 0 | -100,00 | ||||
2024-04-08 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
D - Sale to Issuer | -968.990 | 0 | -100,00 | ||||
2024-04-08 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
D - Sale to Issuer | -858.035 | 0 | -100,00 | ||||
2024-04-08 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
D - Sale to Issuer | -11.103.333 | 0 | -100,00 | ||||
2024-04-08 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
D - Sale to Issuer | -90.442 | 0 | -100,00 | ||||
2024-04-08 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
D - Sale to Issuer | -2.650.177 | 0 | -100,00 | ||||
2024-04-08 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
D - Sale to Issuer | -949.862 | 0 | -100,00 | ||||
2024-04-08 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
D - Sale to Issuer | -190.000 | 0 | -100,00 | ||||
2024-04-08 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
D - Sale to Issuer | -134.180 | 0 | -100,00 | ||||
2024-02-14 |
|
4 | TNYA |
Tenaya Therapeutics, Inc.
Common Stock |
P - Purchase | 2.222.222 | 13.599.275 | 19,53 | 4,50 | 9.999.999 | 61.196.738 | |
2023-11-17 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 5.840 | 949.862 | 0,62 | 0,62 | 3.627 | 589.959 | |
2023-11-17 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 1.460 | 134.180 | 1,10 | 0,62 | 907 | 83.339 | |
2023-11-17 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 16.791 | 944.022 | 1,81 | 0,71 | 11.880 | 667.896 | |
2023-11-17 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 2.720 | 132.720 | 2,09 | 0,71 | 1.919 | 93.621 | |
2023-03-14 |
|
4 | TNYA |
Tenaya Therapeutics, Inc.
Common Stock |
P - Purchase | 6.779 | 11.377.053 | 0,06 | 2,60 | 17.596 | 29.530.279 | |
2023-02-10 |
|
4 | TNYA |
Tenaya Therapeutics, Inc.
Common Stock |
P - Purchase | 1.500.000 | 11.370.274 | 15,20 | 2,60 | 3.900.000 | 29.562.712 | |
2023-02-01 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 176.730 | 927.231 | 23,55 | 5,00 | 883.403 | 4.634.857 | |
2023-02-01 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 7.542 | 750.501 | 1,02 | 5,00 | 37.707 | 3.752.205 | |
2023-01-25 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 9.900 | 742.959 | 1,35 | 5,00 | 49.494 | 3.714.349 | |
2023-01-23 |
|
4 | TNYA |
Tenaya Therapeutics, Inc.
Common Stock |
P - Purchase | 69.739 | 9.870.274 | 0,71 | 2,50 | 174.201 | 24.654.957 | |
2023-01-23 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 500 | 733.059 | 0,07 | 5,00 | 2.498 | 3.662.363 | |
2023-01-23 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 37.639 | 732.559 | 5,42 | 5,00 | 188.105 | 3.661.037 | |
2023-01-19 |
|
4 | TNYA |
Tenaya Therapeutics, Inc.
Common Stock |
P - Purchase | 135.688 | 9.800.535 | 1,40 | 2,52 | 341.432 | 24.661.086 | |
2023-01-19 |
|
4 | TNYA |
Tenaya Therapeutics, Inc.
Common Stock |
P - Purchase | 49.463 | 9.664.847 | 0,51 | 2,49 | 123.395 | 24.110.894 | |
2023-01-17 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 5.378 | 694.920 | 0,78 | 4,95 | 26.603 | 3.437.491 | |
2023-01-12 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 209.000 | 689.542 | 43,49 | 4,76 | 994.840 | 3.282.220 | |
2023-01-12 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 100.070 | 480.542 | 26,30 | 4,84 | 484.519 | 2.326.688 | |
2022-12-14 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 300 | 380.472 | 0,08 | 4,98 | 1.493 | 1.893.495 | |
2022-11-23 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 4.330 | 380.172 | 1,15 | 5,00 | 21.646 | 1.900.518 | |
2022-11-23 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 35.997 | 375.842 | 10,59 | 5,00 | 179.942 | 1.878.759 | |
2022-11-23 |
|
4 | TNYA |
Tenaya Therapeutics, Inc.
Common Stock |
P - Purchase | 9.615.384 | 9.615.384 | 2,60 | 24.999.998 | 24.999.998 | ||
2022-11-07 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 35.058 | 339.845 | 11,50 | 4,72 | 165.320 | 1.602.573 | |
2022-11-07 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 104.090 | 304.787 | 51,86 | 4,99 | 519.107 | 1.520.003 | |
2022-10-31 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 76.877 | 200.697 | 62,09 | 4,86 | 373.638 | 975.428 | |
2022-10-27 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 72.774 | 123.820 | 142,57 | 4,85 | 353.041 | 600.676 | |
2022-10-27 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 51.046 | 51.046 | 4,75 | 242.387 | 242.387 | ||
2022-10-19 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 80.000 | 190.000 | 72,73 | 3,79 | 303.256 | 720.233 | |
2022-10-19 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 50.000 | 130.000 | 62,50 | 3,18 | 159.140 | 413.764 | |
2022-06-13 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 32.477 | 90.442 | 56,03 | 13,50 | 438.440 | 1.220.967 | |
2022-06-13 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 951.684 | 2.650.177 | 56,03 | 13,50 | 12.847.734 | 35.777.390 | |
2022-06-06 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 1.129 | 57.965 | 1,99 | 13,03 | 14.715 | 755.475 | |
2022-06-06 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 33.071 | 1.698.493 | 1,99 | 13,03 | 431.024 | 22.136.969 | |
2022-06-02 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 3.036 | 56.836 | 5,64 | 13,45 | 40.834 | 764.444 | |
2022-06-02 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 88.964 | 1.665.422 | 5,64 | 13,45 | 1.196.566 | 22.399.926 | |
2022-06-02 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 2.040 | 53.800 | 3,94 | 13,47 | 27.470 | 724.460 | |
2022-06-02 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 59.766 | 1.576.458 | 3,94 | 13,47 | 804.797 | 21.228.268 | |
2022-05-31 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 89 | 51.760 | 0,17 | 13,45 | 1.197 | 696.239 | |
2022-05-31 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 2.621 | 1.516.692 | 0,17 | 13,45 | 35.256 | 20.401.479 | |
2022-05-31 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 667 | 51.671 | 1,31 | 13,49 | 9.000 | 697.223 | |
2022-05-31 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 19.534 | 1.514.071 | 1,31 | 13,49 | 263.582 | 20.430.117 | |
2022-05-27 |
|
4 | RAPT |
RAPT Therapeutics, Inc.
Common Stock |
P - Purchase | 63 | 42.189 | 0,15 | 12,45 | 785 | 525.460 | |
2022-05-27 |
|
4 | RAPT |
RAPT Therapeutics, Inc.
Common Stock |
P - Purchase | 1.837 | 1.236.261 | 0,15 | 12,45 | 22.880 | 15.397.507 | |
2022-05-26 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 1.429 | 51.004 | 2,88 | 13,43 | 19.198 | 685.234 | |
2022-05-26 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 41.863 | 1.494.537 | 2,88 | 13,43 | 562.425 | 20.078.955 | |
2022-05-26 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 588 | 49.575 | 1,20 | 13,37 | 7.860 | 662.719 | |
2022-05-26 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 17.240 | 1.452.674 | 1,20 | 13,37 | 230.464 | 19.419.346 | |
2022-05-25 |
|
4 | RAPT |
RAPT Therapeutics, Inc.
Common Stock |
P - Purchase | 538 | 42.126 | 1,29 | 12,00 | 6.457 | 505.600 | |
2022-05-25 |
|
4 | RAPT |
RAPT Therapeutics, Inc.
Common Stock |
P - Purchase | 15.776 | 1.234.424 | 1,29 | 12,00 | 189.345 | 14.815.680 | |
2022-05-25 |
|
4 | RAPT |
RAPT Therapeutics, Inc.
Common Stock |
P - Purchase | 338 | 41.588 | 0,82 | 12,50 | 4.225 | 519.821 | |
2022-05-25 |
|
4 | RAPT |
RAPT Therapeutics, Inc.
Common Stock |
P - Purchase | 9.898 | 1.218.648 | 0,82 | 12,50 | 123.718 | 15.232.247 | |
2022-05-23 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 628 | 48.987 | 1,30 | 13,48 | 8.464 | 660.227 | |
2022-05-23 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 18.406 | 1.435.434 | 1,30 | 13,48 | 248.069 | 19.346.205 | |
2022-05-23 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 682 | 48.359 | 1,43 | 13,25 | 9.040 | 640.984 | |
2022-05-23 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 19.984 | 1.417.028 | 1,43 | 13,25 | 264.882 | 18.782.281 | |
2022-05-20 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Stock Option (Right to Buy) |
A - Award | 24.222 | 24.222 | |||||
2022-05-19 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 2.067 | 47.677 | 4,53 | 13,20 | 27.292 | 629.522 | |
2022-05-19 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 60.583 | 1.397.044 | 4,53 | 13,20 | 799.932 | 18.446.429 | |
2022-05-19 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 2.939 | 45.610 | 6,89 | 13,42 | 39.433 | 611.954 | |
2022-05-19 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 86.110 | 1.336.461 | 6,89 | 13,42 | 1.155.346 | 17.931.431 | |
2022-05-17 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 1.094 | 42.671 | 2,63 | 12,90 | 14.114 | 550.520 | |
2022-05-17 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 32.072 | 1.250.351 | 2,63 | 12,90 | 413.777 | 16.131.403 | |
2022-05-17 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 4.269 | 41.577 | 11,44 | ||||
2022-05-17 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 125.096 | 1.218.279 | 11,44 | ||||
2022-05-13 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 17 | 37.308 | 0,05 | 11,81 | 201 | 440.447 | |
2022-05-13 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 485 | 1.093.183 | 0,04 | 11,81 | 5.726 | 12.905.791 | |
2022-05-13 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 2.728 | 37.291 | 7,89 | 11,62 | 31.702 | 433.362 | |
2022-05-13 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 79.945 | 1.092.698 | 7,89 | 11,62 | 929.049 | 12.698.353 | |
2022-05-13 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 88 | 34.563 | 0,26 | 11,85 | 1.043 | 409.478 | |
2022-05-13 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 2.564 | 1.012.753 | 0,25 | 11,85 | 30.376 | 11.998.389 | |
2022-05-13 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 2.657 | 34.475 | 8,35 | 11,23 | 29.827 | 387.009 | |
2022-05-13 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 77.866 | 1.010.189 | 8,35 | 11,23 | 874.108 | 11.340.180 | |
2022-05-12 |
|
4 | RAPT |
RAPT Therapeutics, Inc.
Common Stock |
P - Purchase | 41.250 | 41.250 | 10,67 | 440.199 | 440.199 | ||
2022-05-12 |
|
4 | RAPT |
RAPT Therapeutics, Inc.
Common Stock |
P - Purchase | 1.208.750 | 1.208.750 | 10,67 | 12.899.176 | 12.899.176 | ||
2022-05-11 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 1.032 | 31.818 | 3,35 | 11,36 | 11.727 | 361.567 | |
2022-05-11 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 30.233 | 932.323 | 3,35 | 11,36 | 343.556 | 10.594.546 | |
2022-05-11 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 2.745 | 30.786 | 9,79 | 10,79 | 29.627 | 332.270 | |
2022-05-11 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 80.430 | 902.090 | 9,79 | 10,79 | 868.073 | 9.736.167 | |
2022-01-26 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 19.791 | 28.041 | 239,89 | ||||
2022-01-26 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 579.910 | 821.660 | 239,88 | ||||
2022-01-26 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 8.250 | 8.250 | |||||
2022-01-26 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 241.750 | 241.750 | |||||
2021-11-16 |
|
4 | ORIC |
Oric Pharmaceuticals, Inc.
Common Stock |
J - Other | 74 | 74 | |||||
2021-11-16 |
|
4 | ORIC |
Oric Pharmaceuticals, Inc.
Common Stock |
J - Other | 86.716 | 103.341 | 521,60 | ||||
2021-11-16 |
|
4 | ORIC |
Oric Pharmaceuticals, Inc.
Common Stock |
J - Other | 86.716 | 103.341 | 521,60 | ||||
2021-11-16 |
|
4 | ORIC |
Oric Pharmaceuticals, Inc.
Common Stock |
J - Other | -287.702 | 0 | -100,00 | ||||
2021-11-16 |
|
4 | ORIC |
Oric Pharmaceuticals, Inc.
Common Stock |
J - Other | 287.702 | 287.702 | |||||
2021-11-16 |
|
4 | ORIC |
Oric Pharmaceuticals, Inc.
Common Stock |
J - Other | -1.200.000 | 3.568.181 | -25,17 | ||||
2021-11-16 |
|
4 | ORIC |
Oric Pharmaceuticals, Inc.
Stock Option (right to buy) |
M - Exercise | -16.625 | 0 | -100,00 | ||||
2021-11-16 |
|
4 | ORIC |
Oric Pharmaceuticals, Inc.
Common Stock |
M - Exercise | 16.625 | 16.625 | 16,00 | 266.000 | 266.000 | ||
2021-09-29 |
|
4 | RAPT |
RAPT Therapeutics, Inc.
Stock Option (Right to Buy) |
M - Exercise | -625 | 6.875 | -8,33 | ||||
2021-09-29 |
|
4 | RAPT |
RAPT Therapeutics, Inc.
Stock Option (Right to Buy) |
M - Exercise | -1.114 | 1.115 | -49,98 | ||||
2021-09-29 |
|
4 | RAPT |
RAPT Therapeutics, Inc.
Stock Option (Right to Buy) |
M - Exercise | -7.500 | 15.000 | -33,33 | ||||
2021-09-29 |
|
4 | RAPT |
RAPT Therapeutics, Inc.
Common Stock |
S - Sale | -625 | 0 | -100,00 | 34,94 | -21.840 | ||
2021-09-29 |
|
4 | RAPT |
RAPT Therapeutics, Inc.
Common Stock |
M - Exercise | 625 | 625 | 19,30 | 12.062 | 12.062 | ||
2021-09-29 |
|
4 | RAPT |
RAPT Therapeutics, Inc.
Common Stock |
S - Sale | -1.114 | 0 | -100,00 | 34,96 | -38.951 | ||
2021-09-29 |
|
4 | RAPT |
RAPT Therapeutics, Inc.
Common Stock |
M - Exercise | 1.114 | 1.114 | 22,20 | 24.731 | 24.731 | ||
2021-09-29 |
|
4 | RAPT |
RAPT Therapeutics, Inc.
Common Stock |
S - Sale | -7.500 | 0 | -100,00 | 34,48 | -258.606 | ||
2021-09-29 |
|
4 | RAPT |
RAPT Therapeutics, Inc.
Common Stock |
M - Exercise | 7.500 | 7.500 | 28,27 | 212.025 | 212.025 | ||
2021-09-16 |
|
4 | RAPT |
RAPT Therapeutics, Inc.
Common Stock |
S - Sale | -4.720 | 0 | -100,00 | 37,70 | -177.957 | ||
2021-09-16 |
|
4 | RAPT |
RAPT Therapeutics, Inc.
Common Stock |
S - Sale | -12.939 | 4.720 | -73,27 | 37,22 | -481.634 | 175.694 | |
2021-09-16 |
|
4 | RAPT |
RAPT Therapeutics, Inc.
Common Stock |
S - Sale | -4.400 | 0 | -100,00 | 37,67 | -165.762 | ||
2021-09-16 |
|
4 | RAPT |
RAPT Therapeutics, Inc.
Common Stock |
S - Sale | -11.476 | 4.400 | -72,29 | 37,21 | -427.066 | 163.741 | |
2021-09-16 |
|
4 | RAPT |
RAPT Therapeutics, Inc.
Common Stock |
S - Sale | -2.926 | 0 | -100,00 | 37,31 | -109.158 | ||
2021-09-16 |
|
4 | RAPT |
RAPT Therapeutics, Inc.
Common Stock |
S - Sale | -32.211 | 2.926 | -91,67 | 36,85 | -1.187.066 | 107.831 | |
2021-09-16 |
|
4 | RAPT |
RAPT Therapeutics, Inc.
Common Stock |
S - Sale | -1.496 | 35.137 | -4,08 | 35,75 | -53.477 | 1.256.028 | |
2021-09-16 |
|
4 | RAPT |
RAPT Therapeutics, Inc.
Common Stock |
S - Sale | -10.807 | 17.659 | -37,96 | 37,31 | -403.261 | 658.942 | |
2021-09-16 |
|
4 | RAPT |
RAPT Therapeutics, Inc.
Common Stock |
S - Sale | -42.151 | 28.466 | -59,69 | 36,92 | -1.556.046 | 1.050.851 | |
2021-09-16 |
|
4 | RAPT |
RAPT Therapeutics, Inc.
Common Stock |
S - Sale | -1.700 | 70.617 | -2,35 | 35,77 | -60.814 | 2.526.196 | |
2021-09-16 |
|
4 | RAPT |
RAPT Therapeutics, Inc.
Common Stock |
S - Sale | -25.351 | 15.876 | -61,49 | 37,27 | -944.844 | 591.706 | |
2021-09-16 |
|
4 | RAPT |
RAPT Therapeutics, Inc.
Common Stock |
S - Sale | -29.634 | 41.227 | -41,82 | 36,79 | -1.090.143 | 1.516.614 | |
2021-09-16 |
|
4 | RAPT |
RAPT Therapeutics, Inc.
Common Stock |
S - Sale | -1.400 | 70.861 | -1,94 | 35,71 | -49.990 | 2.530.241 | |
2021-09-14 |
|
4 | RAPT |
RAPT Therapeutics, Inc.
Common Stock |
S - Sale | -4.788 | 36.633 | -11,56 | 35,28 | -168.942 | 1.292.577 | |
2021-09-14 |
|
4 | RAPT |
RAPT Therapeutics, Inc.
Common Stock |
S - Sale | -4.726 | 72.261 | -6,14 | 35,27 | -166.692 | 2.548.739 | |
2021-09-14 |
|
4 | RAPT |
RAPT Therapeutics, Inc.
Common Stock |
S - Sale | -4.803 | 72.317 | -6,23 | 35,25 | -169.309 | 2.549.218 | |
2021-09-14 |
|
4 | RAPT |
RAPT Therapeutics, Inc.
Common Stock |
S - Sale | -7.231 | 41.421 | -14,86 | 35,19 | -254.494 | 1.457.808 | |
2021-09-14 |
|
4 | RAPT |
RAPT Therapeutics, Inc.
Common Stock |
S - Sale | -7.320 | 76.987 | -8,68 | 35,19 | -257.572 | 2.708.980 | |
2021-09-14 |
|
4 | RAPT |
RAPT Therapeutics, Inc.
Common Stock |
S - Sale | -7.187 | 77.120 | -8,52 | 35,19 | -252.940 | 2.714.169 | |
2021-09-14 |
|
4 | RAPT |
RAPT Therapeutics, Inc.
Common Stock |
J - Other | 48.652 | 48.652 | |||||
2021-09-14 |
|
4 | RAPT |
RAPT Therapeutics, Inc.
Common Stock |
J - Other | 84.307 | 84.307 | |||||
2021-09-14 |
|
4 | RAPT |
RAPT Therapeutics, Inc.
Common Stock |
J - Other | 84.307 | 84.307 | |||||
2021-09-14 |
|
4 | RAPT |
RAPT Therapeutics, Inc.
Common Stock |
J - Other | 72 | 163 | 79,12 | ||||
2021-09-14 |
|
4 | RAPT |
RAPT Therapeutics, Inc.
Common Stock |
J - Other | -279.710 | 0 | -100,00 | ||||
2021-09-14 |
|
4 | RAPT |
RAPT Therapeutics, Inc.
Common Stock |
J - Other | 279.710 | 279.710 | |||||
2021-09-14 |
|
4 | RAPT |
RAPT Therapeutics, Inc.
Common Stock |
J - Other | -1.166.666 | 1.402.008 | -45,42 | ||||
2021-09-07 | 3 | EFTR |
eFFECTOR Therapeutics, Inc.
Common Stock |
4.309.329 | ||||||||
2021-09-03 |
|
4 | RAPT |
RAPT Therapeutics, Inc.
Common Stock |
S - Sale | -18.556 | 0 | -100,00 | 35,43 | -657.469 | ||
2021-09-03 |
|
4 | RAPT |
RAPT Therapeutics, Inc.
Common Stock |
S - Sale | -18.545 | 0 | -100,00 | 35,43 | -657.083 | ||
2021-09-03 |
|
4 | RAPT |
RAPT Therapeutics, Inc.
Common Stock |
S - Sale | -7.064 | 18.556 | -27,57 | 35,46 | -250.484 | 657.981 | |
2021-09-03 |
|
4 | RAPT |
RAPT Therapeutics, Inc.
Common Stock |
S - Sale | -8.805 | 25.620 | -25,58 | 35,06 | -308.681 | 898.173 | |
2021-09-03 |
|
4 | RAPT |
RAPT Therapeutics, Inc.
Common Stock |
S - Sale | -8.976 | 18.545 | -32,62 | 35,39 | -317.674 | 656.335 | |
2021-09-03 |
|
4 | RAPT |
RAPT Therapeutics, Inc.
Common Stock |
S - Sale | -6.904 | 27.521 | -20,06 | 35,02 | -241.753 | 963.684 | |
2021-08-24 |
|
4 | RAPT |
RAPT Therapeutics, Inc.
Common Stock |
S - Sale | -7.100 | 0 | -100,00 | 31,77 | -225.532 | ||
2021-08-24 |
|
4 | RAPT |
RAPT Therapeutics, Inc.
Common Stock |
S - Sale | -4.318 | 7.100 | -37,82 | 30,94 | -133.602 | 219.680 | |
2021-08-24 |
|
4 | RAPT |
RAPT Therapeutics, Inc.
Common Stock |
S - Sale | -3.463 | 34.425 | -9,14 | 31,76 | -109.978 | 1.093.273 | |
2021-08-24 |
|
4 | RAPT |
RAPT Therapeutics, Inc.
Common Stock |
S - Sale | -2.200 | 37.888 | -5,49 | 30,79 | -67.740 | 1.166.606 | |
2021-08-24 |
|
4 | RAPT |
RAPT Therapeutics, Inc.
Common Stock |
S - Sale | -3.486 | 34.425 | -9,20 | 31,76 | -110.707 | 1.093.252 | |
2021-08-24 |
|
4 | RAPT |
RAPT Therapeutics, Inc.
Common Stock |
S - Sale | -2.300 | 37.911 | -5,72 | 30,81 | -70.853 | 1.167.875 | |
2021-08-24 |
|
4 | RAPT |
RAPT Therapeutics, Inc.
Common Stock |
S - Sale | -2.100 | 11.418 | -15,53 | 32,38 | -68.005 | 369.750 | |
2021-08-24 |
|
4 | RAPT |
RAPT Therapeutics, Inc.
Common Stock |
S - Sale | -12.354 | 13.518 | -47,75 | 31,42 | -388.123 | 424.692 | |
2021-08-24 |
|
4 | RAPT |
RAPT Therapeutics, Inc.
Common Stock |
S - Sale | -8.204 | 25.872 | -24,08 | 30,94 | -253.856 | 800.555 | |
2021-08-24 |
|
4 | RAPT |
RAPT Therapeutics, Inc.
Common Stock |
S - Sale | -2.007 | 40.088 | -4,77 | 32,39 | -65.012 | 1.298.555 | |
2021-08-24 |
|
4 | RAPT |
RAPT Therapeutics, Inc.
Common Stock |
S - Sale | -13.623 | 42.095 | -24,45 | 31,40 | -427.810 | 1.321.930 | |
2021-08-24 |
|
4 | RAPT |
RAPT Therapeutics, Inc.
Common Stock |
S - Sale | -7.278 | 55.718 | -11,55 | 30,92 | -225.026 | 1.722.728 | |
2021-08-24 |
|
4 | RAPT |
RAPT Therapeutics, Inc.
Common Stock |
S - Sale | -2.200 | 40.211 | -5,19 | 32,35 | -71.168 | 1.300.786 | |
2021-08-24 |
|
4 | RAPT |
RAPT Therapeutics, Inc.
Common Stock |
S - Sale | -12.969 | 42.411 | -23,42 | 31,41 | -407.373 | 1.332.185 | |
2021-08-24 |
|
4 | RAPT |
RAPT Therapeutics, Inc.
Common Stock |
S - Sale | -7.605 | 55.380 | -12,07 | 30,93 | -235.198 | 1.712.721 | |
2021-08-24 |
|
4 | RAPT |
RAPT Therapeutics, Inc.
Common Stock |
S - Sale | -1.670 | 34.076 | -4,67 | 30,07 | -50.222 | 1.024.774 | |
2021-08-24 |
|
4 | RAPT |
RAPT Therapeutics, Inc.
Common Stock |
S - Sale | -1.429 | 62.996 | -2,22 | 30,08 | -42.985 | 1.894.932 | |
2021-08-24 |
|
4 | RAPT |
RAPT Therapeutics, Inc.
Common Stock |
S - Sale | -1.440 | 62.985 | -2,24 | 30,09 | -43.327 | 1.895.086 | |
2021-08-20 |
|
4 | RAPT |
RAPT Therapeutics, Inc.
Common Stock |
J - Other | 35.746 | 35.746 | |||||
2021-08-20 |
|
4 | RAPT |
RAPT Therapeutics, Inc.
Common Stock |
J - Other | 64.425 | 64.425 | |||||
2021-08-20 |
|
4 | RAPT |
RAPT Therapeutics, Inc.
Common Stock |
J - Other | 64.425 | 64.425 | |||||
2021-08-20 |
|
4 | RAPT |
RAPT Therapeutics, Inc.
Common Stock |
J - Other | 91 | 91 | |||||
2021-08-20 |
|
4 | RAPT |
RAPT Therapeutics, Inc.
Common Stock |
J - Other | -208.403 | 0 | -100,00 | ||||
2021-08-20 |
|
4 | RAPT |
RAPT Therapeutics, Inc.
Common Stock |
J - Other | 208.403 | 208.403 | |||||
2021-08-20 |
|
4 | RAPT |
RAPT Therapeutics, Inc.
Common Stock |
J - Other | -1.317.005 | 2.568.674 | -33,89 | ||||
2021-08-04 |
|
4 | TNYA |
Tenaya Therapeutics, Inc.
Series C Preferred Stock |
C - Conversion | -213.306 | 0 | -100,00 | ||||
2021-08-04 |
|
4 | TNYA |
Tenaya Therapeutics, Inc.
Series C Preferred Stock |
C - Conversion | -188.881 | 0 | -100,00 | ||||
2021-08-04 |
|
4 | TNYA |
Tenaya Therapeutics, Inc.
Series B Preferred Stock |
C - Conversion | -533.781 | 0 | -100,00 | ||||
2021-08-04 |
|
4 | TNYA |
Tenaya Therapeutics, Inc.
Series B Preferred Stock |
C - Conversion | -472.659 | 0 | -100,00 | ||||
2021-08-04 |
|
4 | TNYA |
Tenaya Therapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -4.209.755 | 0 | -100,00 | ||||
2021-08-04 |
|
4 | TNYA |
Tenaya Therapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -3.727.742 | 0 | -100,00 | ||||
2021-08-04 |
|
4 | TNYA |
Tenaya Therapeutics, Inc.
Common Stock |
C - Conversion | 4.956.842 | 4.985.570 | 17.254,39 | ||||
2021-08-04 |
|
4 | TNYA |
Tenaya Therapeutics, Inc.
Common Stock |
C - Conversion | 4.389.282 | 4.414.720 | 17.254,82 | ||||
2021-07-29 | 3 | TNYA |
Tenaya Therapeutics, Inc.
Common Stock |
25.438 | ||||||||
2021-07-29 | 3 | TNYA |
Tenaya Therapeutics, Inc.
Common Stock |
28.728 | ||||||||
2021-06-10 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Stock Option (Right to Buy) |
A - Award | 19.619 | 19.619 | |||||
2021-05-07 |
|
4 | NRIX |
Nurix Therapeutics, Inc.
Common Stock |
J - Other | 7.752 | 48.406 | 19,07 | ||||
2021-05-07 |
|
4 | NRIX |
Nurix Therapeutics, Inc.
Common Stock |
J - Other | 17.829 | 139.383 | 14,67 | ||||
2021-05-07 |
|
4 | NRIX |
Nurix Therapeutics, Inc.
Common Stock |
J - Other | 17.829 | 139.383 | 14,67 | ||||
2021-05-07 |
|
4 | NRIX |
Nurix Therapeutics, Inc.
Common Stock |
J - Other | -49.689 | 0 | -100,00 | ||||
2021-05-07 |
|
4 | NRIX |
Nurix Therapeutics, Inc.
Common Stock |
J - Other | 49.689 | 49.689 | |||||
2021-05-07 |
|
4 | NRIX |
Nurix Therapeutics, Inc.
Common Stock |
J - Other | -1.000.000 | 989.000 | -50,28 | ||||
2021-05-07 |
|
4 | NRIX |
Nurix Therapeutics, Inc.
Common Stock |
J - Other | 30.347 | 40.654 | 294,43 | ||||
2021-05-07 |
|
4 | NRIX |
Nurix Therapeutics, Inc.
Common Stock |
J - Other | 111.247 | 121.554 | 1.079,33 | ||||
2021-05-07 |
|
4 | NRIX |
Nurix Therapeutics, Inc.
Common Stock |
J - Other | 105.874 | 116.181 | 1.027,20 | ||||
2021-05-07 |
|
4 | NRIX |
Nurix Therapeutics, Inc.
Common Stock |
J - Other | -438.338 | 0 | -100,00 | ||||
2021-05-07 |
|
4 | NRIX |
Nurix Therapeutics, Inc.
Common Stock |
J - Other | 10.307 | 10.307 | |||||
2021-05-07 |
|
4 | NRIX |
Nurix Therapeutics, Inc.
Common Stock |
J - Other | 10.307 | 10.307 | |||||
2021-05-07 |
|
4 | NRIX |
Nurix Therapeutics, Inc.
Common Stock |
J - Other | 10.307 | 10.307 | |||||
2021-05-07 |
|
4 | NRIX |
Nurix Therapeutics, Inc.
Common Stock |
J - Other | 438.338 | 438.338 | |||||
2021-05-07 |
|
4 | NRIX |
Nurix Therapeutics, Inc.
Common Stock |
J - Other | -2.000.000 | 1.394.333 | -58,92 | ||||
2021-02-19 |
|
4 | CNST |
CONSTELLATION PHARMACEUTICALS INC
Common Stock |
S - Sale | -10.000 | 99.155 | -9,16 | 36,95 | -369.503 | 3.663.807 | |
2020-12-16 |
|
4 | CNST |
CONSTELLATION PHARMACEUTICALS INC
Warrant (right to buy) |
X - Other | -30.107 | 0 | -100,00 | ||||
2020-12-16 |
|
4 | CNST |
CONSTELLATION PHARMACEUTICALS INC
Common Stock |
X - Other | 30.107 | 2.584.957 | 1,18 | 1,55 | 46.666 | 4.006.683 | |
2020-11-18 |
|
4 | RVMD |
Revolution Medicines, Inc.
Common Stock |
S - Sale | -1.075.133 | 2.429.180 | -30,68 | 36,40 | -39.134.841 | 88.422.152 | |
2020-11-18 |
|
4 | RVMD |
Revolution Medicines, Inc.
Common Stock |
S - Sale | -952.023 | 2.151.026 | -30,68 | 36,40 | -34.653.637 | 78.297.346 | |
2020-09-23 |
|
4 | RAPT |
RAPT Therapeutics, Inc.
Common Stock |
S - Sale | -608.000 | 3.835.679 | -13,68 | 30,85 | -18.756.800 | 118.330.697 | |
2020-09-03 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 27.595 | 1.827.025 | 1,53 | 17,67 | 487.604 | 32.283.532 | |
2020-09-03 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 36.494 | 1.799.430 | 2,07 | 17,64 | 643.754 | 31.741.945 | |
2020-08-31 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 26.135 | 1.762.936 | 1,50 | 17,89 | 467.555 | 31.538.925 | |
2020-08-31 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 36.359 | 1.736.801 | 2,14 | 17,79 | 646.827 | 30.897.690 | |
2020-08-25 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 100 | 1.700.442 | 0,01 | 18,00 | 1.800 | 30.607.956 | |
2020-08-25 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 11.024 | 1.700.342 | 0,65 | 17,96 | 197.991 | 30.538.142 | |
2020-08-25 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 7.321 | 1.689.318 | 0,44 | 17,97 | 131.558 | 30.357.044 | |
2020-08-19 |
|
4 | RAPT |
RAPT Therapeutics, Inc.
Common Stock |
S - Sale | -538.654 | 4.443.679 | -10,81 | 22,75 | -12.254.378 | 101.093.697 | |
2020-08-17 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 6.425 | 1.681.997 | 0,38 | 17,89 | 114.943 | 30.090.926 | |
2020-08-17 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 37.993 | 1.675.572 | 2,32 | 17,49 | 664.498 | 29.305.754 | |
2020-08-17 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 19.895 | 1.637.579 | 1,23 | 17,89 | 355.922 | 29.296.288 | |
2020-08-03 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 732 | 1.617.684 | 0,05 | 17,99 | 13.169 | 29.102.135 | |
2020-07-30 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 4.105 | 1.616.952 | 0,25 | 17,99 | 73.849 | 29.088.966 | |
2020-07-29 |
|
4 | NRIX |
Nurix Therapeutics, Inc.
Series D Preferred Stock |
C - Conversion | -686.274 | 0 | -100,00 | ||||
2020-07-29 |
|
4 | NRIX |
Nurix Therapeutics, Inc.
Series D Preferred Stock |
C - Conversion | -686.274 | 0 | -100,00 | ||||
2020-07-29 |
|
4 | NRIX |
Nurix Therapeutics, Inc.
Series B Preferred Stock |
C - Conversion | -1.989.000 | 0 | -100,00 | ||||
2020-07-29 |
|
4 | NRIX |
Nurix Therapeutics, Inc.
Series B Preferred Stock |
C - Conversion | -1.836.000 | 0 | -100,00 | ||||
2020-07-29 |
|
4 | NRIX |
Nurix Therapeutics, Inc.
Series A-2 Preferred Stock |
C - Conversion | -875.000 | 0 | -100,00 | ||||
2020-07-29 |
|
4 | NRIX |
Nurix Therapeutics, Inc.
Series A-1 Preferred Stock |
C - Conversion | -600.000 | 0 | -100,00 | ||||
2020-07-29 |
|
4 | NRIX |
Nurix Therapeutics, Inc.
Common Stock |
C - Conversion | 686.274 | 686.274 | |||||
2020-07-29 |
|
4 | NRIX |
Nurix Therapeutics, Inc.
Common Stock |
C - Conversion | 686.274 | 686.274 | |||||
2020-07-29 |
|
4 | NRIX |
Nurix Therapeutics, Inc.
Common Stock |
C - Conversion | 1.989.000 | 1.989.000 | |||||
2020-07-29 |
|
4 | NRIX |
Nurix Therapeutics, Inc.
Common Stock |
C - Conversion | 1.836.000 | 3.394.333 | 117,82 | ||||
2020-07-29 |
|
4 | NRIX |
Nurix Therapeutics, Inc.
Common Stock |
C - Conversion | 875.000 | 1.558.333 | 128,05 | ||||
2020-07-29 |
|
4 | NRIX |
Nurix Therapeutics, Inc.
Common Stock |
C - Conversion | 600.000 | 683.333 | 720,00 | ||||
2020-07-28 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 3.834 | 1.612.847 | 0,24 | 17,99 | 68.974 | 29.015.118 | |
2020-07-28 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 68.749 | 1.609.013 | 4,46 | 17,93 | 1.232.670 | 28.849.603 | |
2020-07-23 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 193 | 1.540.264 | 0,01 | 18,00 | 3.474 | 27.724.752 | |
2020-07-23 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Stock Option (Right to Buy) |
M - Exercise | -24.000 | 0 | -100,00 | ||||
2020-07-23 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
M - Exercise | 24.000 | 44.000 | 120,00 | 13,35 | 320.400 | 587.400 | |
2020-07-23 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Stock Option (Right to Buy) |
A - Award | 16.806 | 16.806 | |||||
2020-07-23 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Stock Option (Right to Buy) |
A - Award | 24.000 | 24.000 | |||||
2020-07-23 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Stock Option (Right to Buy) |
A - Award | 24.000 | 24.000 | |||||
2020-07-23 | 3 | NRIX |
Nurix Therapeutics, Inc.
Common Stock |
166.666 | ||||||||
2020-07-23 | 3 | NRIX |
Nurix Therapeutics, Inc.
Common Stock |
166.666 | ||||||||
2020-07-23 | 3 | NRIX |
Nurix Therapeutics, Inc.
Common Stock |
166.666 | ||||||||
2020-07-23 | 3 | NRIX |
Nurix Therapeutics, Inc.
Common Stock |
166.666 | ||||||||
2020-07-23 | 3 | NRIX |
Nurix Therapeutics, Inc.
Common Stock |
166.666 | ||||||||
2020-07-23 | 3 | NRIX |
Nurix Therapeutics, Inc.
Common Stock |
166.666 | ||||||||
2020-07-23 | 3 | NRIX |
Nurix Therapeutics, Inc.
Common Stock |
166.666 | ||||||||
2020-07-23 | 3 | NRIX |
Nurix Therapeutics, Inc.
Common Stock |
166.666 | ||||||||
2020-07-23 | 3 | NRIX |
Nurix Therapeutics, Inc.
Common Stock |
166.666 | ||||||||
2020-07-23 | 3 | NRIX |
Nurix Therapeutics, Inc.
Common Stock |
166.666 | ||||||||
2020-07-23 | 3 | NRIX |
Nurix Therapeutics, Inc.
Common Stock |
166.666 | ||||||||
2020-07-23 | 3 | NRIX |
Nurix Therapeutics, Inc.
Common Stock |
166.666 | ||||||||
2020-06-22 |
|
4 | RAPT |
RAPT Therapeutics, Inc.
Stock Option (Right to Buy) |
J - Other | 22.500 | 22.500 | |||||
2020-06-19 |
|
4 | RVMD |
Revolution Medicines, Inc.
Stock Option (Right to Buy) |
J - Other | 25.318 | 25.318 | |||||
2020-06-19 |
|
4 | RVMD |
Revolution Medicines, Inc.
Common Stock |
J - Other | 7.234 | 7.234 | |||||
2020-06-19 |
|
4 | RVMD |
Revolution Medicines, Inc.
Stock Option (Right to Buy) |
J - Other | 36.168 | 36.168 | |||||
2020-05-22 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Stock Option (Right to Buy) |
A - Award | 16.806 | 16.806 | |||||
2020-04-28 |
|
4 | ORIC |
Oric Pharmaceuticals, Inc.
Series D Preferred Stock |
C - Conversion | -151.515 | 0 | -100,00 | ||||
2020-04-28 |
|
4 | ORIC |
Oric Pharmaceuticals, Inc.
Series C Preferred Stock |
C - Conversion | -416.666 | 0 | -100,00 | ||||
2020-04-28 |
|
4 | ORIC |
Oric Pharmaceuticals, Inc.
Series B Preferred Stock |
C - Conversion | -625.000 | 0 | -100,00 | ||||
2020-04-28 |
|
4 | ORIC |
Oric Pharmaceuticals, Inc.
Series A Preferred Stock |
C - Conversion | -3.500.000 | 0 | -100,00 | ||||
2020-04-28 |
|
4 | ORIC |
Oric Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 151.515 | 4.768.181 | 3,28 | ||||
2020-04-28 |
|
4 | ORIC |
Oric Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 416.666 | 4.616.666 | 9,92 | ||||
2020-04-28 |
|
4 | ORIC |
Oric Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 625.000 | 4.200.000 | 17,48 | ||||
2020-04-28 |
|
4 | ORIC |
Oric Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 3.500.000 | 3.575.000 | 4.666,67 | ||||
2020-04-23 | 3 | ORIC |
Oric Pharmaceuticals, Inc.
Common Stock |
150.000 | ||||||||
2020-04-23 | 3 | ORIC |
Oric Pharmaceuticals, Inc.
Common Stock |
150.000 | ||||||||
2020-04-23 | 3 | ORIC |
Oric Pharmaceuticals, Inc.
Common Stock |
150.000 | ||||||||
2020-04-23 | 3 | ORIC |
Oric Pharmaceuticals, Inc.
Common Stock |
150.000 | ||||||||
2020-04-23 | 3 | ORIC |
Oric Pharmaceuticals, Inc.
Common Stock |
150.000 | ||||||||
2020-04-09 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 112.602 | 17.896.978 | 0,63 | 14,95 | 1.683.400 | 267.559.821 | |
2020-04-07 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 123.728 | 17.784.376 | 0,70 | 14,38 | 1.779.209 | 255.739.327 | |
2020-04-07 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 14.587 | 17.660.648 | 0,08 | 12,41 | 181.025 | 219.168.642 | |
2020-04-02 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 14.850 | 17.646.061 | 0,08 | 12,40 | 184.140 | 218.811.156 | |
2020-04-02 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 118.067 | 17.631.211 | 0,67 | 12,26 | 1.447.501 | 216.158.647 | |
2020-04-02 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 118.067 | 17.513.144 | 0,68 | 12,53 | 1.479.380 | 219.439.694 | |
2020-03-25 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 2.416 | 17.395.077 | 0,01 | 12,49 | 30.176 | 217.264.512 | |
2020-03-25 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 128.377 | 17.392.661 | 0,74 | 12,22 | 1.568.767 | 212.538.317 | |
2020-03-25 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 170.387 | 17.264.284 | 1,00 | 11,63 | 1.981.601 | 200.783.623 | |
2020-03-23 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 143.082 | 17.093.897 | 0,84 | 11,77 | 1.684.075 | 201.195.168 | |
2020-03-23 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 148.464 | 16.950.815 | 0,88 | 11,59 | 1.720.698 | 196.459.946 | |
2020-03-23 |
|
4 | CNST |
CONSTELLATION PHARMACEUTICALS INC
Common Stock |
P - Purchase | 5.539 | 6.051.376 | 0,09 | 23,15 | 128.228 | 140.089.354 | |
2020-03-23 |
|
4 | CNST |
CONSTELLATION PHARMACEUTICALS INC
Common Stock |
P - Purchase | 36.135 | 6.045.837 | 0,60 | 22,38 | 808.701 | 135.305.832 | |
2020-03-06 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 8.307 | 16.802.351 | 0,05 | 18,00 | 149.526 | 302.442.318 | |
2020-03-04 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 9.986 | 16.794.044 | 0,06 | 17,96 | 179.349 | 301.621.030 | |
2020-03-04 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 38.758 | 16.784.058 | 0,23 | 17,99 | 697.256 | 301.945.203 | |
2020-03-04 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 14.124 | 16.745.300 | 0,08 | 17,90 | 252.820 | 299.740.870 | |
2020-02-28 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 37.800 | 16.731.176 | 0,23 | 17,91 | 676.998 | 299.655.362 | |
2020-02-28 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 33.896 | 16.693.376 | 0,20 | 17,91 | 607.077 | 298.978.364 | |
2020-02-28 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 3.751 | 16.659.480 | 0,02 | 18,00 | 67.518 | 299.870.640 | |
2020-02-18 |
|
4 | RVMD |
Revolution Medicines, Inc.
Series C Preferred Stock |
C - Conversion | -99.758 | 0 | -100,00 | ||||
2020-02-18 |
|
4 | RVMD |
Revolution Medicines, Inc.
Series B Preferred Stock |
C - Conversion | -2.740.043 | 0 | -100,00 | ||||
2020-02-18 |
|
4 | RVMD |
Revolution Medicines, Inc.
Series A Preferred Stock |
C - Conversion | -5.137.583 | 0 | -100,00 | ||||
2020-02-18 |
|
4 | RVMD |
Revolution Medicines, Inc.
Common Stock |
C - Conversion | 7.977.384 | 7.977.384 | |||||
2020-02-10 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 44.900 | 16.655.729 | 0,27 | 15,96 | 716.604 | 265.825.435 | |
2019-11-13 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 15 | 16.610.829 | 0,00 | 12,00 | 180 | 199.329.948 | |
2019-11-06 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 8.409 | 16.610.814 | 0,05 | 11,99 | 100.824 | 199.163.660 | |
2019-11-04 |
|
4 | RAPT |
RAPT Therapeutics, Inc.
Series C-2 Preferred Stock |
C - Conversion | -872.410 | 0 | -100,00 | ||||
2019-11-04 |
|
4 | RAPT |
RAPT Therapeutics, Inc.
Series C-2 Preferred Stock |
C - Conversion | -872.410 | 0 | -100,00 | ||||
2019-11-04 |
|
4 | RAPT |
RAPT Therapeutics, Inc.
Series C Preferred Stock |
C - Conversion | -8.724.100 | 0 | -100,00 | ||||
2019-11-04 |
|
4 | RAPT |
RAPT Therapeutics, Inc.
Series C Preferred Stock |
C - Conversion | -4.362.050 | 0 | -100,00 | ||||
2019-11-04 |
|
4 | RAPT |
RAPT Therapeutics, Inc.
Series B Preferred Stock |
C - Conversion | -7.000.000 | 0 | -100,00 | ||||
2019-11-04 |
|
4 | RAPT |
RAPT Therapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -14.781.963 | 0 | -100,00 | ||||
2019-11-04 |
|
4 | RAPT |
RAPT Therapeutics, Inc.
Common Stock |
C - Conversion | 145.401 | 145.401 | |||||
2019-11-04 |
|
4 | RAPT |
RAPT Therapeutics, Inc.
Common Stock |
C - Conversion | 145.401 | 145.401 | |||||
2019-11-04 |
|
4 | RAPT |
RAPT Therapeutics, Inc.
Common Stock |
C - Conversion | 1.454.016 | 1.454.016 | |||||
2019-11-04 |
|
4 | RAPT |
RAPT Therapeutics, Inc.
Common Stock |
P - Purchase | 625.000 | 4.982.333 | 14,34 | 12,00 | 7.500.000 | 59.787.996 | |
2019-11-04 |
|
4 | RAPT |
RAPT Therapeutics, Inc.
Common Stock |
C - Conversion | 727.008 | 4.357.333 | 20,03 | ||||
2019-11-04 |
|
4 | RAPT |
RAPT Therapeutics, Inc.
Common Stock |
C - Conversion | 1.166.666 | 3.630.325 | 47,36 | ||||
2019-11-04 |
|
4 | RAPT |
RAPT Therapeutics, Inc.
Common Stock |
C - Conversion | 2.463.659 | 2.463.659 | |||||
2019-10-30 | 3 | RAPT |
RAPT Therapeutics, Inc.
Common Stock |
100.000 | ||||||||
2019-10-30 | 3 | RAPT |
RAPT Therapeutics, Inc.
Common Stock |
100.000 | ||||||||
2019-10-30 | 3 | RAPT |
RAPT Therapeutics, Inc.
Common Stock |
100.000 | ||||||||
2019-10-24 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 2.087 | 16.602.405 | 0,01 | 11,86 | 24.752 | 196.904.523 | |
2019-10-24 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 2.300 | 16.600.318 | 0,01 | 12,00 | 27.600 | 199.203.816 | |
2019-10-21 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 43.400 | 16.598.018 | 0,26 | 11,94 | 518.196 | 198.180.335 | |
2019-10-21 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 34.721 | 16.554.618 | 0,21 | 11,29 | 392.000 | 186.901.637 | |
2019-10-21 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 6.818 | 16.519.897 | 0,04 | 10,62 | 72.407 | 175.441.306 | |
2019-10-16 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 34.900 | 16.513.079 | 0,21 | 10,26 | 358.074 | 169.424.191 | |
2019-10-16 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 33.200 | 16.478.179 | 0,20 | 10,31 | 342.292 | 169.890.025 | |
2019-10-16 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 34.900 | 16.444.979 | 0,21 | 10,36 | 361.564 | 170.369.982 | |
2019-10-11 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 17.724 | 16.410.079 | 0,11 | 10,57 | 187.343 | 173.454.535 | |
2019-10-11 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 17.724 | 16.392.355 | 0,11 | 10,50 | 186.102 | 172.119.728 | |
2019-10-11 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 17.724 | 16.374.631 | 0,11 | 10,26 | 181.848 | 168.003.714 | |
2019-10-07 |
|
4 | CNST |
CONSTELLATION PHARMACEUTICALS INC
Common Stock |
P - Purchase | 80.000 | 159.155 | 101,07 | 8,50 | 680.000 | 1.352.818 | |
2019-10-07 |
|
4 | CNST |
CONSTELLATION PHARMACEUTICALS INC
Common Stock |
P - Purchase | 1.331.764 | 6.009.702 | 28,47 | 8,50 | 11.319.994 | 51.082.467 | |
2019-08-09 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 152 | 16.356.907 | 0,00 | 13,99 | 2.126 | 228.833.129 | |
2019-08-09 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 12 | 16.356.755 | 0,00 | 13,98 | 168 | 228.667.435 | |
2019-08-09 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 224.500 | 16.356.743 | 1,39 | 14,00 | 3.143.000 | 228.994.402 | |
2019-08-07 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 310 | 16.132.243 | 0,00 | 13,96 | 4.328 | 225.206.112 | |
2019-08-07 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 5.824 | 16.131.933 | 0,04 | 13,98 | 81.400 | 225.469.575 | |
2019-08-05 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 1.782 | 16.126.109 | 0,01 | 13,97 | 24.898 | 225.315.608 | |
2019-08-05 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 2.600 | 16.124.327 | 0,02 | 13,98 | 36.346 | 225.405.192 | |
2019-07-31 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 8.855 | 16.121.727 | 0,05 | 13,91 | 123.195 | 224.293.527 | |
2019-07-31 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 19.201 | 16.112.872 | 0,12 | 13,58 | 260.727 | 218.793.466 | |
2019-07-26 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 30.059 | 16.093.671 | 0,19 | 13,59 | 408.634 | 218.783.801 | |
2019-07-26 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 30.753 | 16.063.612 | 0,19 | 13,37 | 411.294 | 214.836.353 | |
2019-07-26 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 29.054 | 16.032.859 | 0,18 | 13,51 | 392.502 | 216.594.305 | |
2019-07-23 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 30.760 | 16.003.805 | 0,19 | 13,35 | 410.535 | 213.593.183 | |
2019-07-23 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 30.760 | 15.973.045 | 0,19 | 13,54 | 416.337 | 216.195.164 | |
2019-07-23 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 6.222 | 15.942.285 | 0,04 | 13,99 | 87.043 | 223.024.596 | |
2019-07-17 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 3.900 | 15.936.063 | 0,02 | 13,86 | 54.055 | 220.878.614 | |
2019-07-17 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 16.188 | 15.932.163 | 0,10 | 13,69 | 221.547 | 218.045.990 | |
2019-07-15 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 21.014 | 15.915.975 | 0,13 | 13,88 | 291.765 | 220.982.172 | |
2019-07-15 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 10.870 | 15.894.961 | 0,07 | 13,87 | 150.752 | 220.440.856 | |
2019-06-26 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 12.240 | 15.884.091 | 0,08 | 13,78 | 168.650 | 218.860.536 | |
2019-06-21 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 3.763 | 15.871.851 | 0,02 | 14,03 | 52.789 | 222.658.262 | |
2019-06-21 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 15.400 | 15.868.088 | 0,10 | 13,86 | 213.385 | 219.871.401 | |
2019-06-21 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 15.214 | 15.852.688 | 0,10 | 13,91 | 211.674 | 220.560.033 | |
2019-06-14 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 10.760 | 15.837.474 | 0,07 | 14,00 | 150.687 | 221.794.321 | |
2019-06-14 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 11.500 | 15.826.714 | 0,07 | 14,13 | 162.508 | 223.648.878 | |
2019-06-14 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 7.500 | 15.815.214 | 0,05 | 14,00 | 104.989 | 221.389.273 | |
2019-06-11 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 10.900 | 15.807.714 | 0,07 | 13,83 | 150.718 | 218.578.004 | |
2019-06-11 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 12.600 | 15.796.814 | 0,08 | 13,66 | 172.176 | 215.860.304 | |
2019-06-06 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 12.600 | 15.784.214 | 0,08 | 13,40 | 168.884 | 211.563.712 | |
2019-06-06 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 12.600 | 15.771.614 | 0,08 | 13,39 | 168.764 | 211.244.998 | |
2019-05-22 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 50.000 | 15.759.014 | 0,32 | 13,50 | 675.000 | 212.746.689 | |
2019-05-17 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Stock Option (Right to Buy) |
A - Award | 24.000 | 24.000 | |||||
2019-05-13 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 17.923 | 15.709.014 | 0,11 | 13,85 | 248.234 | 217.569.844 | |
2019-05-09 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 57.000 | 15.691.091 | 0,36 | 14,10 | 803.700 | 221.244.383 | |
2019-04-10 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Series D Convertible Preferred Stock |
C - Conversion | -3.400.000 | 0 | -100,00 | ||||
2019-04-10 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Series C Convertible Preferred Stock |
C - Conversion | -2.377.334 | 0 | -100,00 | ||||
2019-04-10 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Series B Convertible Preferred Stock |
C - Conversion | -8.488.933 | 0 | -100,00 | ||||
2019-04-10 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Series A Convertible Preferred Stock |
C - Conversion | -12.300.000 | 0 | -100,00 | ||||
2019-04-10 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
P - Purchase | 1.875.000 | 15.634.091 | 13,63 | 16,00 | 30.000.000 | 250.145.456 | |
2019-04-10 |
|
4 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
C - Conversion | 13.283.134 | 13.759.091 | 2.790,83 | ||||
2019-04-03 | 3 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
951.914 | ||||||||
2019-04-03 | 3 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
951.914 | ||||||||
2019-04-03 | 3 | NGM |
NGM BIOPHARMACEUTICALS INC
Common Stock |
951.914 | ||||||||
2019-04-02 |
|
4 | IMDZ |
IMMUNE DESIGN CORP.
Common Stock |
U - Other | -6.642.942 | 0 | -100,00 | 5,85 | -38.861.211 | ||
2018-10-02 |
|
4 | GRTS |
Gritstone Oncology, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -929.022 | 0 | -100,00 | ||||
2018-10-02 |
|
4 | GRTS |
Gritstone Oncology, Inc.
Series A Convertible Preferred Stock |
C - Conversion | -2.173.912 | 0 | -100,00 | ||||
2018-10-02 |
|
4 | GRTS |
Gritstone Oncology, Inc.
Common Stock |
C - Conversion | 3.102.934 | 3.102.934 | |||||
2018-07-23 |
|
4 | CNST |
CONSTELLATION PHARMACEUTICALS INC
Series F Preferred Stock |
C - Conversion | -300.000 | 0 | -100,00 | ||||
2018-07-23 |
|
4 | CNST |
CONSTELLATION PHARMACEUTICALS INC
Series F Preferred Stock |
C - Conversion | -20.000.000 | 0 | -100,00 | ||||
2018-07-23 |
|
4 | CNST |
CONSTELLATION PHARMACEUTICALS INC
Series E-1 Preferred Stock |
C - Conversion | -6.502.856 | 0 | -100,00 | ||||
2018-07-23 |
|
4 | CNST |
CONSTELLATION PHARMACEUTICALS INC
Series E Preferred Stock |
C - Conversion | -444.444 | 0 | -100,00 | ||||
2018-07-23 |
|
4 | CNST |
CONSTELLATION PHARMACEUTICALS INC
Series E Preferred Stock |
C - Conversion | -3.555.555 | 0 | -100,00 | ||||
2018-07-23 |
|
4 | CNST |
CONSTELLATION PHARMACEUTICALS INC
Series D Preferred Stock |
C - Conversion | -970.159 | 0 | -100,00 | ||||
2018-07-23 |
|
4 | CNST |
CONSTELLATION PHARMACEUTICALS INC
Series B Preferred Stock |
C - Conversion | -8.333.333 | 0 | -100,00 | ||||
2018-07-23 |
|
4 | CNST |
CONSTELLATION PHARMACEUTICALS INC
Series A Preferred Stock |
C - Conversion | -11.000.000 | 0 | -100,00 | ||||
2018-07-23 |
|
4 | CNST |
CONSTELLATION PHARMACEUTICALS INC
Common Stock |
C - Conversion | 79.155 | 79.155 | |||||
2018-07-23 |
|
4 | CNST |
CONSTELLATION PHARMACEUTICALS INC
Common Stock |
C - Conversion | 4.666.888 | 4.677.939 | 42.230,46 | ||||
2018-07-18 | 3 | CNST |
CONSTELLATION PHARMACEUTICALS INC
Common Stock |
22.102 | ||||||||
2018-07-18 | 3 | CNST |
CONSTELLATION PHARMACEUTICALS INC
Common Stock |
22.102 | ||||||||
2018-07-18 | 3 | CNST |
CONSTELLATION PHARMACEUTICALS INC
Common Stock |
22.102 | ||||||||
2018-07-18 | 3 | CNST |
CONSTELLATION PHARMACEUTICALS INC
Common Stock |
22.102 | ||||||||
2018-07-18 | 3 | CNST |
CONSTELLATION PHARMACEUTICALS INC
Common Stock |
22.102 | ||||||||
2018-07-18 | 3 | CNST |
CONSTELLATION PHARMACEUTICALS INC
Common Stock |
22.102 | ||||||||
2018-07-18 | 3 | CNST |
CONSTELLATION PHARMACEUTICALS INC
Common Stock |
22.102 | ||||||||
2018-07-18 | 3 | CNST |
CONSTELLATION PHARMACEUTICALS INC
Common Stock |
22.102 | ||||||||
2018-07-18 | 3 | CNST |
CONSTELLATION PHARMACEUTICALS INC
Common Stock |
22.102 | ||||||||
2018-07-18 | 3 | CNST |
CONSTELLATION PHARMACEUTICALS INC
Common Stock |
22.102 | ||||||||
2018-03-19 |
|
4 | RCUS |
Arcus Biosciences, Inc.
Series C Preferred Stock |
C - Conversion | -470.427 | 0 | -100,00 | ||||
2018-03-19 |
|
4 | RCUS |
Arcus Biosciences, Inc.
Series C Preferred Stock |
C - Conversion | -427.660 | 0 | -100,00 | ||||
2018-03-19 |
|
4 | RCUS |
Arcus Biosciences, Inc.
Series B Preferred Stock |
C - Conversion | -875.087 | 0 | -100,00 | ||||
2018-03-19 |
|
4 | RCUS |
Arcus Biosciences, Inc.
Series A Preferred Stock |
C - Conversion | -1.767.676 | 0 | -100,00 | ||||
2018-03-19 |
|
4 | RCUS |
Arcus Biosciences, Inc.
Common Stock |
C - Conversion | 470.427 | 470.427 | |||||
2018-03-19 |
|
4 | RCUS |
Arcus Biosciences, Inc.
Common Stock |
C - Conversion | 427.660 | 3.070.423 | 16,18 | ||||
2018-03-19 |
|
4 | RCUS |
Arcus Biosciences, Inc.
Common Stock |
C - Conversion | 875.087 | 2.642.763 | 49,50 | ||||
2018-03-19 |
|
4 | RCUS |
Arcus Biosciences, Inc.
Common Stock |
C - Conversion | 1.767.676 | 1.767.676 | |||||
2017-10-30 |
|
4 | IMDZ |
Immune Design Corp.
Common Stock |
P - Purchase | 2.681.000 | 6.642.942 | 67,67 | 4,10 | 10.992.100 | 27.236.062 | |
2016-09-22 |
|
4 | IMDZ |
Immune Design Corp.
Common Stock |
P - Purchase | 800.000 | 3.961.942 | 25,30 | 6,25 | 5.000.000 | 24.762.138 | |
2014-07-31 |
|
4 | IMDZ |
Immune Design Corp.
Series C Preferred Stock |
C - Conversion | -428.134 | 0 | -100,00 | ||||
2014-07-31 |
|
4 | IMDZ |
Immune Design Corp.
Series C Preferred Stock |
X - Other | 428.134 | 428.134 | |||||
2014-07-31 |
|
4 | IMDZ |
Immune Design Corp.
Series C Preferred Stock Warrant (right to buy) |
X - Other | -428.134 | 0 | -100,00 | ||||
2014-07-31 |
|
4 | IMDZ |
Immune Design Corp.
Series C Preferred Stock |
C - Conversion | -856.269 | 0 | -100,00 | ||||
2014-07-31 |
|
4 | IMDZ |
Immune Design Corp.
Series B Preferred Stock |
C - Conversion | -744.580 | 0 | -100,00 | ||||
2014-07-31 |
|
4 | IMDZ |
Immune Design Corp.
Series A Preferred Stock |
C - Conversion | -733.943 | 0 | -100,00 | ||||
2014-07-31 |
|
4 | IMDZ |
Immune Design Corp.
Common Stock |
P - Purchase | 399.016 | 3.161.942 | 14,44 | 12,00 | 4.788.192 | 37.943.304 | |
2014-07-31 |
|
4 | IMDZ |
Immune Design Corp.
Common Stock |
C - Conversion | 428.134 | 2.762.926 | 18,34 | ||||
2014-07-31 |
|
4 | IMDZ |
Immune Design Corp.
Common Stock |
C - Conversion | 856.269 | 2.334.792 | 57,91 | ||||
2014-07-31 |
|
4 | IMDZ |
Immune Design Corp.
Common Stock |
C - Conversion | 744.580 | 1.478.523 | 101,45 | ||||
2014-07-31 |
|
4 | IMDZ |
Immune Design Corp.
Common Stock |
C - Conversion | 733.943 | 733.943 |